When.com Web Search

  1. Ads

    related to: phosphorus dose for adults with cancer

Search results

  1. Results From The WOW.Com Content Network
  2. Fosfestrol - Wikipedia

    en.wikipedia.org/wiki/Fosfestrol

    Fosfestrol sodium is given at a dosage of 600 to 1200 mg/day by slow intravenous infusion over a period of 1 hour for a treatment duration of 5 to 10 days in men with prostate cancer. [ 3 ] [ 2 ] Following this, it is given at a dose of 300 mg/day for 10 to 20 days. [ 3 ]

  3. Pertuzumab/trastuzumab/hyaluronidase - Wikipedia

    en.wikipedia.org/wiki/Pertuzumab/trastuzumab/...

    The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. [5] [10]The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and ...

  4. Pafolacianine - Wikipedia

    en.wikipedia.org/wiki/Pafolacianine

    Scientists from Purdue University designed and developed OTL38 and licensed it to On Target Laboratories in 2013. [9] [10] The safety and effectiveness of pafolacianine was evaluated in a randomized, multi-center, open-label study of women diagnosed with ovarian cancer or with high clinical suspicion of ovarian cancer who were scheduled to undergo surgery.

  5. Estramustine phosphate - Wikipedia

    en.wikipedia.org/wiki/Estramustine_phosphate

    Estramustine phosphate (EMP), also known as estradiol normustine phosphate and sold under the brand names Emcyt and Estracyt, is a dual estrogen and chemotherapy medication which is used in the treatment of prostate cancer in men. [7] [4] [8] [9] [10] [3] [1] [11] [5] [12] It is taken multiple times a day by mouth or by injection into a vein ...

  6. Venetoclax - Wikipedia

    en.wikipedia.org/wiki/Venetoclax

    Venetoclax is also indicated as part of a combination therapy for acute myeloid leukemia (AML). [7] For this purpose it is used with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed adults who are age 75 years or older, or those with other health problems where intensive chemotherapy cannot be used.

  7. Tumor lysis syndrome - Wikipedia

    en.wikipedia.org/wiki/Tumor_lysis_syndrome

    Hyperphosphatemia causes acute kidney injury in tumor lysis syndrome, because of deposition of calcium phosphate crystals in the kidney parenchyma. [2] Hypocalcemia. Because of the hyperphosphatemia, calcium is precipitated to form calcium phosphate, leading to hypocalcemia. [2] Symptoms of hypocalcemia include (but are not limited to): [9] tetany